Printer Friendly

SCIOS NOVA ELECTS NEW DIRECTORS

 MOUNTAIN VIEW, Calif., Feb. 10 /PRNewswire/ -- Scios Nova Inc. (NASDAQ: SCIO) today announced that William F. Miller and Eugene L. Step have been elected to the company's board of directors. Dr. Miller is professor of public and private management and professor of computer science at Stanford University. He also serves as president emeritus and member of the board of directors of SRI International. Step recently retired as executive vice president, president of the pharmaceuticals division and a member of the board of directors and executive committee of Eli Lilly and Co.
 In 1990, Miller retired as president and chief executive officer at SRI International. He is an authority on international business and public policy for industrial development and is actively engaged in projects in Australia, Singapore, Japan, Indonesia, China and Slovenia. Miller is a member of the National Academy of Engineering and a fellow of the American Academy of Arts and Sciences, the Institute of Electrical and Electronic Engineers and the American Association for the Advancement of Sciences.
 Step joined Eli Lilly and Co. in 1956, and held marketing positions throughout his 36-year career with Lilly. Step is a past chairman of the board of directors of the Pharmaceutical Manufacturers Association and immediate past president of the International Federation of Pharmaceutical Manufacturers Association. He is a member of the board of directors of Voluntary Hospitals of America and the American Foundation for Pharmaceutical Education and is a trustee of the National Foundation for Infectious Diseases.
 Scios Nova is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios Nova focuses its efforts in four areas: cardiovascular disease, inflammation, metabolic disorders and tissue repair. The company's drug discovery technology encompasses both biotechnology techniques and small molecule design to develop new biopharmaceutical products. Scios Nova develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 2/10/93
 /CONTACT: Kira Bacon of Scios Nova, 415-940-6629/
 (SCIO)


CO: Scios Nova Inc. ST: California IN: MTC SU: PER

SG-GT -- SJ003 -- 5016 02/10/93 09:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:344
Previous Article:NEWELL DECLARES QUARTERLY CASH DIVIDEND ON ITS COMMON STOCK
Next Article:ACUSON REPORTS 4TH QUARTER AND YEAR-END RESULTS
Topics:


Related Articles
RICHARD L. CASEY ELECTED CHAIRMAN OF SCIOS NOVA INC. BOARD OF DIRECTORS
SCIOS NOVA EXERCISES OPTION TO PURCHASE INTERESTS IN NOVA TECHNOLOGY LIMITED PARTNERSHIP
SCIOS NOVA HOLDS ANNUAL MEETING
SCIOS NOVA HOLDS ANNUAL MEETING
SCIOS NOVA ANNOUNCES CFO DEPARTURE
SCIOS ELECTS BURTON E. SOBEL, M.D., TO BOARD OF DIRECTORS
SCIOS ANNOUNCES NEW EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER
Scios Hires Vice President of Cardiorenal Research
Scios Promotes Rosenkranz to President
Scios Names Richard B. Brewer as Chief Executive Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters